PfSPZ Vaccine

Last updated

PfSPZ Vaccine is a metabolically active non-replicating whole sporozoite (SPZ) malaria vaccine being developed by Sanaria against Plasmodium falciparum (Pf) malaria. Clinical trials have been safe, extremely well tolerated and highly efficacious. The first generation PfSPZ product is attenuated by gamma irradiation; the second generation vaccines PfSPZ-CVac and PfSPZ LARC2 are, respectively, attenuated chemically and genetically. Multiple studies are ongoing with trials of the PfSPZ vaccines. All three products are produced using the same manufacturing process. These products are stored and distributed below -150 °C using liquid nitrogen (LN2) vapor phase (LNVP) freezers and cryoshippers.

Contents

History

In the first half of the 20th century there were first attempts to protect people from malaria.[ citation needed ] At the beginning Pasteur's approach of developing bacterial vaccines was used as a big hope in eradication of this fatal disease. But inactivated malaria sporozoites (by formalin) were ineffective in inducing the protection.[ citation needed ]

In 1948 inactivated merozoites with an adjuvant were used for preventing lethal malaria to kill a group of monkeys. But the strong toxicity of the adjuvant and inability to obtain sufficient count of parasites from human blood stopped further efforts in this way. [1]

In 1967 irradiated malaria sporozoites (extracted from salivary glands of infected mosquitos) induced immune response in mice without the need of the adjuvant and similar evidence obtained in human volunteer trials. The mice were exposed to irradiated mosquitos infected by malaria parasites. Mice and volunteers did not acquire malaria because mosquitos and the sporozoites were irradiated and their immune cells triggered response that could protect them from following infection. [2] [3] Yet this approach was not further developed due to problems with obtaining sufficient number of sporozoites and with the harvesting of parasites.[ citation needed ]

Later, modern adjuvants and the possibility of preparing of single parasite proteins provided another way to create a malaria vaccine. RTS,S is a subunit vaccine based on coat protein of sporozoites of the Plasmodium falciparum. The RTS,S vaccine was endorsed by the World Health Organization in October 2021 for broad use in children, making it the first malaria vaccine to receive this recommendation. [4] As of April 2022, 1 million children in Ghana, Kenya and Malawi have received at least one shot of the vaccine, with more doses being provided as the vaccine production ramps up. [5] RTS,S reduces hospital admissions from severe malaria by around 30%. [5]

PfSPZ development

In 2003 Sanaria ran trials in which falciparum sporozoites were manually dissected from salivary glands of mosquitos, irradiated and preserved before inoculation with one goal: to develop and commercialize a non-replicating, metabolically active PfSPZ vaccine. [6]

In human volunteer trials PfSPZ was applied subcutaneously (SC) or intradermally (ID) and such as it showed only modest immune response. When PfSPZ Vaccine was injected intravenously (IV) to nonhuman primates or mice it finally triggers CD8+ T-cells producing IFNγ. These T cells are believed to be the main immunologic mechanism to fight malaria in liver.

Two first clinical trials of IV administration of PfSPZ were conducted in 2013. Previous ID or IC clinical trials didn't trigger adequate immune response. A 2014 phase 1 trial with the PfSPZ Vaccine found that more than half of the participants were protected from malaria infection for over a year after the trial. [7] [8]

In 2014 Sanaria promoted an Indiegogo campaign to develop a robot that could dissect salivary glands of mosquitos, to make preparation and further development of vaccine much faster and easier. [9] The crowdfunding campaign ended, after being backed by $45,024 of the $250,000 goal. [10]

The PfSPZ Vaccine candidate was granted fast track designation by the U.S. Food and Drug Administration in September 2016. [11]

A study published in 2017 reported complete protection after 10 weeks with three doses of PfSPZ-CVac. [12] In April 2019, a phase 3 trial in Bioko was announced, scheduled to start in early 2020. [13] Another study of the PfSPZ vaccine was published in December 2022, reporting vaccine efficacy at up to 48% at 6 months follow up, and up to 46% efficacy at 18 months. [14] [15]

Mechanism

CD8+ T cells play a key role in killing Plasmodium developing in the liver. Mice or monkeys which received monoclonal antibody to the CD8 lost protection by this type of vaccine. Once the antibody application was stopped, the protection was returned. [16] [17] Plasmodium is injected by infected mosquito into the bloodstream of the host in the form of sporozoites, which travel to the liver and invade liver cells, where sporozoites divide and produce tens of thousands merozoites per one cell. RTS,S is prepared to stop malaria in the phase after the injection. The PfSPZ vaccine is made of attenuated sporozites, which are active and travel to liver cells, where CD8+ T cells producing IFNγ are activated. Frequencies of PfSPZ-specific CD3+CD4+, CD3+CD8+, CD3+γδ T cells are dose-dependent. PfSPZ-specific CD3+CD8+ T cells were found in 7 of 12 protected subjects in a human volunteer trial. [18] These cells are required for protection in most individuals and are primarily situated in the liver because of the persistence of parasite antigens and retained as tissue memory cells. [19]

Distribution

PfSPZ vaccines are cryopreserved and stored in LNVP freezers [20] below -150 °C and distributed using dry vapor cryoshippers that also maintain temperature below -150 °C. Cryoshippers [21] are self-contained mobile storage units that have hold times of ~14 to 28 days or more depending on model and packaging and are highly suited for last-mile transportation, particularly in Africa. Cryoshippers are used extensively in the livestock breeding, CAR-T and cellular therapies industries. LNVP distribution uses a simple hub-and-spoke model [22] and cryoshippers stay at the immunization sites as temporary storage units that may be recharged with LN2. Advantages of the LNVP cold chain are a) independence from electricity, b) no requirement for fridges, freezers or refrigerated transport, c) no narrow temperature requirements, d) reduced chances for temperature deviations, e) no moving parts, and f) energy efficiency. LN2 is widely available, including in African countries, making LNVP distribution easier than the 2-8 °C and the dry ice and ultralow freezer-based cold chains of Ervebo (vs ebola) [23] [24] and certain SARS-CoV-2 [25] vaccines. Modeling LNVP distribution [26] also indicated costs would be no different per 3-dose regimen than the 2-8 °C cold chain for lyophilized vaccines.

Related Research Articles

<span class="mw-page-title-main">Malaria</span> Mosquito-borne infectious disease

Malaria is a mosquito-borne infectious disease that affects humans and other vertebrates. Human malaria causes symptoms that typically include fever, fatigue, vomiting, and headaches. In severe cases, it can cause jaundice, seizures, coma, or death. Symptoms usually begin 10 to 15 days after being bitten by an infected Anopheles mosquito. If not properly treated, people may have recurrences of the disease months later. In those who have recently survived an infection, reinfection usually causes milder symptoms. This partial resistance disappears over months to years if the person has no continuing exposure to malaria.

<i>Plasmodium</i> Genus of parasitic protists that can cause malaria

Plasmodium is a genus of unicellular eukaryotes that are obligate parasites of vertebrates and insects. The life cycles of Plasmodium species involve development in a blood-feeding insect host which then injects parasites into a vertebrate host during a blood meal. Parasites grow within a vertebrate body tissue before entering the bloodstream to infect red blood cells. The ensuing destruction of host red blood cells can result in malaria. During this infection, some parasites are picked up by a blood-feeding insect, continuing the life cycle.

<i>Plasmodium falciparum</i> Protozoan species of malaria parasite

Plasmodium falciparum is a unicellular protozoan parasite of humans, and the deadliest species of Plasmodium that causes malaria in humans. The parasite is transmitted through the bite of a female Anopheles mosquito and causes the disease's most dangerous form, falciparum malaria. It is responsible for around 50% of all malaria cases. P. falciparum is therefore regarded as the deadliest parasite in humans. It is also associated with the development of blood cancer and is classified as a Group 2A (probable) carcinogen.

<span class="mw-page-title-main">Gametocyte</span> Eukaryotic germ stem cell

A gametocyte is a eukaryotic germ cell that divides by mitosis into other gametocytes or by meiosis into gametids during gametogenesis. Male gametocytes are called spermatocytes, and female gametocytes are called oocytes.

<i>Plasmodium vivax</i> Species of single-celled organism

Plasmodium vivax is a protozoal parasite and a human pathogen. This parasite is the most frequent and widely distributed cause of recurring malaria. Although it is less virulent than Plasmodium falciparum, the deadliest of the five human malaria parasites, P. vivax malaria infections can lead to severe disease and death, often due to splenomegaly. P. vivax is carried by the female Anopheles mosquito; the males do not bite.

<i>Plasmodium ovale</i> Species of single-celled organism

Plasmodium ovale is a species of parasitic protozoon that causes tertian malaria in humans. It is one of several species of Plasmodium parasites that infect humans, including Plasmodium falciparum and Plasmodium vivax which are responsible for most cases of malaria in the world. P. ovale is rare compared to these two parasites, and substantially less dangerous than P. falciparum.

<i>Plasmodium malariae</i> Species of single-celled organism

Plasmodium malariae is a parasitic protozoan that causes malaria in humans. It is one of several species of Plasmodium parasites that infect other organisms as pathogens, also including Plasmodium falciparum and Plasmodium vivax, responsible for most malarial infection. Found worldwide, it causes a so-called "benign malaria", not nearly as dangerous as that produced by P. falciparum or P. vivax. The signs include fevers that recur at approximately three-day intervals – a quartan fever or quartan malaria – longer than the two-day (tertian) intervals of the other malarial parasite.

<i>Plasmodium knowlesi</i> Species of single-celled organism

Plasmodium knowlesi is a parasite that causes malaria in humans and other primates. It is found throughout Southeast Asia, and is the most common cause of human malaria in Malaysia. Like other Plasmodium species, P. knowlesi has a life cycle that requires infection of both a mosquito and a warm-blooded host. While the natural warm-blooded hosts of P. knowlesi are likely various Old World monkeys, humans can be infected by P. knowlesi if they are fed upon by infected mosquitoes. P. knowlesi is a eukaryote in the phylum Apicomplexa, genus Plasmodium, and subgenus Plasmodium. It is most closely related to the human parasite Plasmodium vivax as well as other Plasmodium species that infect non-human primates.

Malaria prophylaxis is the preventive treatment of malaria. Several malaria vaccines are under development.

Malaria vaccines are vaccines that prevent malaria, a mosquito-borne infectious disease which annually affects an estimated 247 million people worldwide and causes 619,000 deaths. The first approved vaccine for malaria is RTS,S, known by the brand name Mosquirix. As of April 2023, the vaccine has been given to 1.5 million children living in areas with moderate-to-high malaria transmission. It requires at least three doses in infants by age 2, and a fourth dose extends the protection for another 1–2 years. The vaccine reduces hospital admissions from severe malaria by around 30%.

Pregnancy-associated malaria (PAM) or placental malaria is a presentation of the common illness that is particularly life-threatening to both mother and developing fetus. PAM is caused primarily by infection with Plasmodium falciparum, the most dangerous of the four species of malaria-causing parasites that infect humans. During pregnancy, a woman faces a much higher risk of contracting malaria and of associated complications. Prevention and treatment of malaria are essential components of prenatal care in areas where the parasite is endemic – tropical and subtropical geographic areas. Placental malaria has also been demonstrated to occur in animal models, including in rodent and non-human primate models.

<span class="mw-page-title-main">RTS,S</span> Malaria vaccine

RTS,S/AS01 is a recombinant protein-based malaria vaccine. It is one of two malaria vaccines approved. As of April 2022, the vaccine has been given to 1 million children living in areas with moderate-to-high malaria transmission, with millions more doses to be provided as the vaccine's production expands. 18 million doses have been allocated for 2023-2025. It requires at least three doses in infants by age 2, with a fourth dose extending the protection for another 1–2 years. The vaccine reduces hospital admissions from severe malaria by around 30% and reduces toddler deaths by 15%.

Plasmodium coatneyi is a parasitic species that is an agent of malaria in nonhuman primates. P. coatneyi occurs in Southeast Asia. The natural host of this species is the rhesus macaque and crab-eating macaque, but there has been no evidence that zoonosis of P. coatneyi can occur through its vector, the female Anopheles mosquito.

Circumsporozoite protein (CSP) is a secreted protein of the sporozoite stage of the malaria parasite and is the antigenic target of RTS,S and other malaria vaccines. The amino-acid sequence of CSP consists of an immunodominant central repeat region flanked by conserved motifs at the N- and C- termini that are implicated in protein processing as the parasite travels from the mosquito to the mammalian vector. The amino acid sequence of CSP was determined in 1984.

Sanaria is a biotechnology company developing vaccines protective against malaria and other infectious diseases as well as related products for use in malaria research. Sanaria's vaccines are based on the use of the sporozoite (SPZ) stage of the malaria parasite, Plasmodium, as an immunogen, and as a platform technology for liver-vectored gene delivery. SPZ are normally introduced into humans by mosquito bite where they migrate to the liver and further develop to liver stages, and eventually back into the blood stream where the parasite infects red blood cells (RBC) and causes malaria. Plasmodium falciparum is the species responsible for more than 95% deaths caused by malaria. The WHO estimates there were 247 million clinical cases and 619,000 deaths in 2021 alone.

Ruth Sonntag Nussenzweig was an Austrian-Brazilian immunologist specializing in the development of malaria vaccines. In a career spanning over 60 years, she was primarily affiliated with New York University (NYU). She served as C.V. Starr Professor of Medical and Molecular Parasitology at Langone Medical Center, Research Professor at the NYU Department of Pathology, and finally Professor Emerita of Microbiology and Pathology at the NYU Department of Microbiology.

Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) is a family of proteins present on the membrane surface of red blood cells that are infected by the malarial parasite Plasmodium falciparum. PfEMP1 is synthesized during the parasite's blood stage inside the RBC, during which the clinical symptoms of falciparum malaria are manifested. Acting as both an antigen and adhesion protein, it is thought to play a key role in the high level of virulence associated with P. falciparum. It was discovered in 1984 when it was reported that infected RBCs had unusually large-sized cell membrane proteins, and these proteins had antibody-binding (antigenic) properties. An elusive protein, its chemical structure and molecular properties were revealed only after a decade, in 1995. It is now established that there is not one but a large family of PfEMP1 proteins, genetically regulated (encoded) by a group of about 60 genes called var. Each P. falciparum is able to switch on and off specific var genes to produce a functionally different protein, thereby evading the host's immune system. RBCs carrying PfEMP1 on their surface stick to endothelial cells, which facilitates further binding with uninfected RBCs, ultimately helping the parasite to both spread to other RBCs as well as bringing about the fatal symptoms of P. falciparum malaria.

Peter Gottfried Kremsner is a specialist in tropical medicine and Full Professor at the University of Tübingen, Germany. Since 1992 he has been leading the Centre de Recherches Médicales de Lambaréné (CERMEL), Gabon, now as president.

Reticulocyte binding protein homologs (RHs) are a superfamily of proteins found in Plasmodium responsible for cell invasion. Together with the family of erythrocyte binding-like proteins (EBLs) they make up the two families of invasion proteins universal to Plasmodium. The two families function cooperatively.

Stephen L. Hoffman is an American physician-scientist, tropical medicine specialist and vaccinologist, who is the founder and chief executive and scientific officer of Sanaria Inc., a company dedicated to developing PfSPZ vaccines to prevent malaria.

References

  1. ↑ Freund, J; Thomson, K. J. (1948). "Immunization of monkeys against malaria by means of killed parasites with adjuvants". The American Journal of Tropical Medicine and Hygiene. 28 (1): 1–22. doi:10.4269/ajtmh.1948.s1-28.1. PMID   18898694.
  2. ↑ Nussenzweig, R. S.; Vanderberg, J; Most, H; Orton, C (1967). "Protective immunity produced by the injection of x-irradiated sporozoites of plasmodium berghei". Nature. 216 (5111): 160–2. Bibcode:1967Natur.216..160N. doi:10.1038/216160a0. PMID   6057225. S2CID   4283134.
  3. ↑ Rieckmann, K. H.; Carson, P. E.; Beaudoin, R. L.; Cassells, J. S.; Sell, K. W. (1974). "Letter: Sporozoite induced immunity in man against an Ethiopian strain of Plasmodium falciparum". Transactions of the Royal Society of Tropical Medicine and Hygiene. 68 (3): 258–9. doi:10.1016/0035-9203(74)90129-1. PMID   4608063.
  4. ↑ Mandavilli A (6 October 2021). "A 'Historical Event': First Malaria Vaccine Approved by W.H.O." The New York Times . Retrieved 6 October 2021.
  5. 1 2 "First malaria vaccine hits 1 million dose milestone — although it has its shortcomings". NPR. 13 May 2022. Retrieved 2 January 2023.
  6. ↑ Luke, T. C.; Hoffman, S. L. (2003). "Rationale and plans for developing a non-replicating, metabolically active, radiation-attenuated Plasmodium falciparum sporozoite vaccine". The Journal of Experimental Biology. 206 (Pt 21): 3803–8. doi: 10.1242/jeb.00644 . PMID   14506215.
  7. ↑ Ishizuka, et al. (2016). "Protection against malaria at 1 year and immune correlates following PfSPZ vaccination". Nature Medicine. 22 (6): 614–623. doi:10.1038/nm.4110. PMID   27158907. S2CID   205396815.
  8. ↑ Feller, Stephen (10 May 2016). "Malaria vaccine shown to be safe, effective in phase 1 trial - More than half of volunteers in the small study did not contract malaria when exposed to mosquitoes more than a year after their last dose of the vaccine". UPI . Retrieved 25 August 2020.
  9. ↑ "Sanaria Inc. To Launch Crowdfunding Campaign For Sporobottm, A Mosquito-Dissecting Robot For Accelerating Manufacture Of Sanaria's Malaria Vaccine". Sanaria. 30 April 2014. Retrieved 25 August 2020.
  10. ↑ "Malaria Vaccine Robot - Robot vs. Mosquito Sanaria - SporoBot". Indiegogo . Retrieved 25 August 2020.
  11. ↑ "SANARIA PfSPZ VACCINE AGAINST MALARIA RECEIVES FDA FAST TRACK DESIGNATION" (PDF). Sanaria Inc. 22 September 2016. Archived from the original (PDF) on 23 October 2016. Retrieved 23 January 2017.
  12. ↑ "Nature report describes complete protection after 10 weeks with three doses of PfSPZ- CVac" (Press release). 15 February 2017.
  13. ↑ Butler, Declan (16 April 2019). "Promising malaria vaccine to be tested in first large field trial - The vaccine can confer up to 100% protection and will be tested in 2,100 people on the west African island of Bioko". Nature . doi:10.1038/d41586-019-01232-4. PMID   32291409. S2CID   145852768 . Retrieved 25 August 2020.
  14. ↑ Payne, January (26 December 2022). "2022 News - A Three-Dose Malaria Vaccine Shows Safety, Efficacy in West African Adults". University of Maryland School of Medicine . Retrieved 11 January 2023.
  15. ↑ Sirima, Sodiomon B.; Ouédraogo, Alphonse; Tiono, Alfred B.; Kaboré, Jean M.; Bougouma, Edith C.; Ouattara, Maurice S.; Kargougou, Désiré; Diarra, Amidou; Henry, Noelie; Ouédraogo, Issa N.; Billingsley, Peter F.; Manoj, Anita; Abebe, Yonas; Kc, Natasha; Ruben, Adam (7 December 2022). "A randomized controlled trial showing safety and efficacy of a whole sporozoite vaccine against endemic malaria". Science Translational Medicine. 14 (674): eabj3776. doi:10.1126/scitranslmed.abj3776. ISSN   1946-6234. PMC  10041996. PMID   36475905. S2CID   254430012.
  16. ↑ Epstein, J. E.; Tewari, K; Lyke, K. E.; Sim, B. K.; Billingsley, P. F.; Laurens, M. B.; Gunasekera, A; Chakravarty, S; James, E. R.; Sedegah, M; Richman, A; Velmurugan, S; Reyes, S; Li, M; Tucker, K; Ahumada, A; Ruben, A. J.; Li, T; Stafford, R; Eappen, A. G.; Tamminga, C; Bennett, J. W.; Ockenhouse, C. F.; Murphy, J. R.; Komisar, J; Thomas, N; Loyevsky, M; Birkett, A; Plowe, C. V.; et al. (2011). "Live attenuated malaria vaccine designed to protect through hepatic CD8⁺ T cell immunity". Science. 334 (6055): 475–80. Bibcode:2011Sci...334..475E. doi: 10.1126/science.1211548 . PMID   21903775. S2CID   206536528.
  17. ↑ Rts, S Clinical Trials; Agnandji, S. T.; Lell, B; Fernandes, J. F.; Abossolo, B. P.; Methogo, B. G.; Kabwende, A. L.; Adegnika, A. A.; Mordmüller, B; Issifou, S; Kremsner, P. G.; Sacarlal, J; Aide, P; Lanaspa, M; Aponte, J. J.; Machevo, S; Acacio, S; Bulo, H; Sigauque, B; MacEte, E; Alonso, P; Abdulla, S; Salim, N; Minja, R; Mpina, M; Ahmed, S; Ali, A. M.; Mtoro, A. T.; Hamad, A. S.; et al. (2012). "A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants" (PDF). New England Journal of Medicine. 367 (24): 2284–95. doi:10.1056/NEJMoa1208394. PMID   23136909. S2CID   13944101.
  18. ↑ Seder, R. A.; Chang, L. J.; Enama, M. E.; Zephir, K. L.; Sarwar, U. N.; Gordon, I. J.; Holman, L. A.; James, E. R.; Billingsley, P. F.; Gunasekera, A; Richman, A; Chakravarty, S; Manoj, A; Velmurugan, S; Li, M; Ruben, A. J.; Li, T; Eappen, A. G.; Stafford, R. E.; Plummer, S. H.; Hendel, C. S.; Novik, L; Costner, P. J.; Mendoza, F. H.; Saunders, J. G.; Nason, M. C.; Richardson, J. H.; Murphy, J; Davidson, S. A.; et al. (2013). "Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine". Science. 341 (6152): 1359–65. Bibcode:2013Sci...341.1359S. doi: 10.1126/science.1241800 . PMID   23929949. S2CID   22462258.
  19. ↑ Cockburn, I. A.; Chen, Y. C.; Overstreet, M. G.; Lees, J. R.; Van Rooijen, N; Farber, D. L.; Zavala, F (2010). "Prolonged antigen presentation is required for optimal CD8+ T cell responses against malaria liver stage parasites". PLOS Pathogens. 6 (5): e1000877. doi: 10.1371/journal.ppat.1000877 . PMC   2865532 . PMID   20463809.
  20. ↑ "Liquid Nitrogen (LN2) Freezers - Isothermal V-Series". BioLife Solutions. Retrieved 4 October 2022.
  21. ↑ "MVE Vapor Shipper Series". MVE Biological Solutions. Retrieved 4 October 2022.
  22. ↑ James, Eric R (11 March 2021). "Disrupting vaccine logistics". International Health. 13 (3): 211–214. doi:10.1093/inthealth/ihab010. ISSN   1876-3413. PMC   8079314 . PMID   33709112.
  23. ↑ Research, Center for Biologics Evaluation and (19 September 2022). "ERVEBO". FDA.
  24. ↑ Jusu, Morrison O.; Glauser, Geoffrey; Seward, Jane F.; Bawoh, Mohamed; Tempel, Judith; Friend, Michael; Littlefield, Daniel; Lahai, Michael; Jalloh, Hassan M.; Sesay, Amara Bangali; Caulker, Amanda F.; Samai, Mohamed; Thomas, Vasavi; Farrell, Nicholas; Widdowson, Marc-Alain (18 May 2018). "Rapid Establishment of a Cold Chain Capacity of -60°C or Colder for the STRIVE Ebola Vaccine Trial During the Ebola Outbreak in Sierra Leone". The Journal of Infectious Diseases. 217 (suppl_1): S48–S55. doi:10.1093/infdis/jix336. ISSN   1537-6613. PMC   6927859 . PMID   29788339.
  25. ↑ Research, Center for Biologics Evaluation and (29 August 2022). "COMIRNATY". FDA.
  26. ↑ Garcia, Cristina Reyes; Manzi, Fatuma; Tediosi, Fabrizio; Hoffman, Stephen L.; James, Eric R. (2 January 2013). "Comparative cost models of a liquid nitrogen vapor phase (LNVP) cold chain-distributed cryopreserved malaria vaccine vs. a conventional vaccine". Vaccine. 31 (2): 380–386. doi:10.1016/j.vaccine.2012.10.109. ISSN   1873-2518. PMC   3666854 . PMID   23146676.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.